3.0000 -0.02 (-0.66%)
After hours: 5:28PM EDT
|Bid||2.8000 x 4000|
|Ask||3.0200 x 1100|
|Day's Range||2.6200 - 3.0400|
|52 Week Range||2.1500 - 6.3000|
|Beta (3Y Monthly)||2.42|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 8, 2018 - May 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.25|
PLYMOUTH MEETING, Pennsylvania, June 26, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) today announced the completion of target enrollment of 198 participants for its pivotal Phase 3 registration trial ("REVEAL 1") of VGX-3100, a novel DNA-based immunotherapy being tested to treat cervical dysplasia caused by human papillomavirus (HPV). Left untreated, cervical dysplasia can progress to cervical cancer. If approved, VGX-3100 would be the first immunotherapy and non-surgical alternative for women with late-stage cervical dysplasia.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is a small-cap stock with a market capitalization of US$240m. While...
PLYMOUTH MEETING, Pennsylvania, June 10, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today that the medical arm of the U.S. Defense Threat Reduction Agency (DTRA) will fund the further development of Inovio's new commercial intradermal delivery device. DTRA's Medical CBRN Defense Consortium will provide $8.14 million to support Inovio in developing a small, portable, battery-powered intradermal device branded as CELLECTRA® 3PSP to be used in the administration of Inovio's vaccines and therapies which include DTRA developed products.
Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The leader of George Mason University is set to become the next president of Georgia Tech. The Board of Regents of the University System of Georgia on Thursday named Ángel Cabrera as the sole finalist for the Georgia Tech presidency. Cabrera is currently president of George Mason University, a renowned research institution and the largest public university in Virginia.
CEO of Inovio Pharmaceuticals Inc (NASDAQ:INO) Jong Joseph Kim sold 2,129,553 shares of INO on 06/03/2019 at an average price of $2.36 a share.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 28) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Arrowhead ...
Inovio Pharmaceuticals Inc. shares fell in the extended session Tuesday after the drug developer said that one of its partners is scaling back on a research collaboration. Inovio shares fell 6.7% after hours, following a 3.7% decline to close at $3.14. In a filing with the Securities and Exchange Commission, Inovio said AstraZeneca PLC subsidiary MedImmune is discontinuing a research agreement with the company with the exception of a drug candidate known as "MEDI0457." The companies will continue evaluating the drug for use in cancers associated with human papillomavirus, or HPV, and Inovio will be eligible for milestone payments should the drug receive market approval.
Shares of Workday W seesawed in extended trading on Tuesday — jumping as much as 2% before falling more than 1% — after the software company reported better-than-expected first-quarter earnings. Inovio Pharmaceuticals INO stock plummeted as much as 11% after news broke that Astrazeneca, a pharmaceutical company, will discontinue its research collaborations with the biotech company. Refinitiv consensus estimates had projected earnings of 49 cents per share and net sales of $479.5 million.
PLYMOUTH MEETING, Pa. and OSLO, Norway, May 21, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO), together with CEPI, today announced it has dosed subjects in a Phase 1, first-in-human clinical trial to evaluate INO-4500, its DNA candidate vaccine to prevent infection from the Lassa virus. Inovio plans to enroll approximately 60 volunteers in this placebo controlled, blinded, dose escalation study evaluating INO-4500 for safety, tolerability and immune responses. This Inovio trial represents the first Lassa candidate vaccine to enter the clinic.
QIAGEN's (QGEN) Sample to Insight workflows and expertise in developing diagnostic solutions will aptly compliment Inovio regarding Precision Medicine in immuno-oncology.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 16) Adverum Biotechnologies Inc (NASDAQ: ADVM )(announced ...
Frankfurt Prime Standard: QIA) today announced a collaboration to co-develop a diagnostic test to identify patients most likely to respond to VGX-3100, Inovio's immunotherapy to treat advanced cervical dysplasia associated with the human papillomavirus virus (HPV). This precision medicine partnership focuses on Inovio's VGX-3100, a late-stage product candidate currently in two pivotal Phase 3 clinical trials (REVEAL 1 and 2) with potential to become the first treatment for HPV infection of the cervix and the first non-surgical treatment for precancerous cervical lesions associated with the virus.
PLYMOUTH MEETING, Pa. and SEOUL, South Korea, May 15, 2019 /PRNewswire/ -- Inovio Pharmaceuticals Inc. (INO) and Plumbline Life Sciences (XKRX:222670) today announced a collaboration to co-develop a novel animal health vaccine for African swine fever (ASF) virus. The vaccine will be developed using Inovio's SynCon® technology and delivered using CELLECTRA® efficacy-enabling devices. Plumbline, based in South Korea, will fund all development and commercialization of the ASF vaccine.
Inovio Pharmaceuticals' (INO) earnings and revenues disappoint with an estimate miss in the first quarter. Shares slip in after-hours trading.
More revenue, more cash, lower expenses, and a lot of pipeline activity were the major stories for the biotech in Q1.